Neuralink: $12.0B valuation, IPO Readiness 66, Series F. Brain-computer interface company developing implantable chips (Telepathy device). Raised $650M Series E at $9B. Track live on The IPO Stack.
Brain-computer interface company developing implantable chips (Telepathy device). Raised $650M Series E at $9B valuation (June 2025). CEO Elon Musk has no IPO plans — company is focused on FDA clinical trials, not public markets.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Neuralink IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Neuralink has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Neuralink is valued at $12.0B as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Neuralink shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Neuralink scores 66/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Neuralink has raised $2.1B in total venture capital and private equity funding, with backing from Andreessen Horowitz.
Neuralink's notable investors include Andreessen Horowitz. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Neuralink is a Healthcare Technology company. Brain-computer interface company developing implantable chips (Telepathy device). Raised $650M Series E at $9B valuation.